ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $80,096 | -43.7% | 15,084 | +1.0% | 0.00% | – |
| Q2 2023 | $142,340 | -3.3% | 14,936 | +11.6% | 0.00% | – |
| Q1 2023 | $147,213 | -30.7% | 13,383 | -6.8% | 0.00% | – |
| Q4 2022 | $212,557 | -4.7% | 14,362 | +22.7% | 0.00% | – |
| Q3 2022 | $223,000 | -5.5% | 11,708 | +5.6% | 0.00% | – |
| Q2 2022 | $236,000 | -0.8% | 11,087 | +11.4% | 0.00% | – |
| Q3 2021 | $238,000 | -24.7% | 9,951 | -13.9% | 0.00% | – |
| Q2 2021 | $316,000 | – | 11,562 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $95,526,552 | 6.92% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $33,000 | 4.12% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $6,259,451 | 2.58% |
| Opaleye Management Inc. | 502,000 | $5,522,000 | 1.65% |
| 1492 Capital Management LLC | 223,516 | $2,458,676 | 1.52% |
| MIRABELLA FINANCIAL SERVICES LLP | 45,299 | $9,849,004 | 1.49% |
| Saturn V Capital Management LP | 178,217 | $1,960,387 | 1.46% |
| AlphaCentric Advisors LLC | 190,000 | $2,090,000 | 1.44% |
| Rubric Capital Management LP | 3,500,000 | $38,500,000 | 1.00% |
| MPM BioImpact LLC | 254,137 | $2,795,507 | 0.73% |